The ongoing shortage of medication at the Fiji Pharmaceuticals Biomedical Services (FPBS) has been linked not to financial issues but to disruptions in the global supply chain. Dr. Jemesa Tudravu, the Permanent Secretary for Health, emphasized that since Fiji does not produce its own medicines, it relies solely on imports, which are facing several challenges.
Despite an increase in the government’s budget for medicines and medical products, delays in delivery are largely due to complications arising from transportation, documentation, and unexpected global events, such as strikes at major ports. Dr. Tudravu explained that any strike or disruption in ports, whether in Australia or Denmark, can significantly affect the entire supply process, from manufacturing to the arrival of products in Fiji.
To counter these supply challenges, Dr. Tudravu highlighted the importance of maintaining strong communication with suppliers. FPBS’s team is continuously engaged with suppliers to explore alternative solutions to ensure timely deliveries. Additionally, they are actively seeking out alternative sourcing options to overcome these shortages.
On the topic of medical testing, he noted that private hospitals are contacted for testing services only when necessary, which affects the costs depending on the agreements made. The government’s commitment to increasing budget allocations for medicines further illustrates a positive step towards enhancing the healthcare system.
This situation showcases the resilience and proactive measures being taken by healthcare officials in Fiji. While the supply chain disruptions are challenging, ongoing communication, exploration of alternatives, and government support offer hope for a more stable supply of medicines in the future.
In summary, the position taken by Dr. Tudravu sheds light on the complexities involved in global medicine supply and highlights the government’s supportive efforts to mitigate the impact of these disruptions on healthcare services in Fiji.
Leave a comment